I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Leber Congenital Amaurosis: A Guide for Families
What Is Leber Congenital Amaurosis?
LCA is not a single disease but a collection of related conditions, all sharing one feature: inherited damage to the retina that begins in infancy. Understanding the biology behind LCA helps families make sense of the diagnosis and why specific genetic testing matters so much.
The retina is the light-sensitive tissue at the back of the eye. It contains specialized cells called photoreceptors, which detect light and convert it into electrical signals sent to the brain. This conversion process is called the visual cycle. In LCA, genetic mutations disrupt one or more steps in this process, leaving photoreceptors unable to do their job properly.
In RPE65-related LCA, one of the most studied subtypes, a defective protein prevents the eye from producing the vitamin A molecules that photoreceptors need to respond to light. In another common subtype caused by CEP290 gene mutations, the problem involves a tiny structure on the surface of retinal cells called the primary cilium, which acts like a signal antenna for the cell. When this structure fails, the photoreceptors cannot function. Regardless of which gene is involved, the result is significant vision loss beginning in the first weeks or months of life.
Mutations in at least 29 different genes are known to cause LCA. A handful of these genes account for the majority of diagnosed cases, according to the National Eye Institute.
- CRX gene: responsible for approximately 20% to 25% of all LCA cases
- CEP290 gene: approximately 15% of cases
- GUCY2D gene: approximately 12% of cases
- CRB1 gene: approximately 10% of cases
- RPE65 gene: approximately 8% of cases
Together, these five genes account for roughly 70% to 80% of known LCA diagnoses. Each gene plays a different role in retinal function, which is why the severity and pace of vision loss can vary considerably from one child to another.
LCA is most commonly inherited in an autosomal recessive pattern. This means a child must receive one defective copy of the relevant gene from each parent in order to develop the condition. Parents who each carry a single defective copy typically experience no vision problems themselves. When both parents are carriers, each pregnancy carries a 25% chance that the child will inherit both defective copies.
A small number of LCA gene mutations follow a dominant inheritance pattern, where only one defective copy is needed to cause disease. The genes IMPDH1 and OTX2 work this way. The CRX gene can cause either dominant or recessive LCA depending on the specific mutation involved. Genetic counseling helps families understand exactly how inheritance applies in their situation.
Who Can Develop LCA?
LCA is a rare condition, but it ranks among the most common causes of severe inherited vision loss in children. Knowing who is at risk and how the disease is passed down helps families make informed decisions about genetic testing and family planning.
LCA affects approximately 1 in 40,000 newborns, according to the National Institutes of Health. Prevalence estimates vary by population, ranging from about 1 in 33,000 to 1 in 81,000. Although rare, LCA accounts for approximately 5% of all inherited retinal dystrophies and is consistently among the leading causes of inherited childhood blindness worldwide, according to the National Eye Institute.
The most significant risk factor for LCA is having two parents who each carry a mutation in one of the associated genes. A family history of any inherited retinal disease, even without a confirmed LCA diagnosis, may indicate carrier status. Genetic counseling is recommended for any family with a known history of inherited eye disease, or when an infant shows early signs of visual impairment.
Signs and Symptoms of LCA
LCA typically becomes apparent in the first weeks or months of life. Recognizing the signs early helps families access timely evaluation, genetic testing, and the developmental support their child needs.
The earliest and most consistent sign of LCA is a lack of visual responsiveness. Parents may notice that their infant does not fix a gaze on faces or nearby objects, does not follow movement with the eyes, or does not seem to react to light. Nystagmus (involuntary, rhythmic movements of the eyes) often develops within the first few months. These signs should be reported to a pediatrician promptly, as timely referral to a retina specialist can make a meaningful difference.
Children with LCA often develop a distinctive behavior called the Franceschetti oculodigital sign. This involves repeatedly pressing, poking, or rubbing the eyes with fingers or knuckles. The pressure on the eye stimulates the photoreceptor cells and produces brief flashes of light called phosphenes. For a child with little or no functional vision, this sensation may feel calming or engaging.
While the behavior is not immediately harmful, persistent and forceful eye rubbing over time can gradually alter the shape of the eye or contribute to other complications. Parents should mention this behavior to their child's eye care provider so that protective strategies can be discussed.
Additional signs that parents or pediatricians may notice include the following.
- Strabismus: misalignment of the eyes when looking at something
- Photophobia: unusual sensitivity to bright light or aversion to light
- Sluggish or absent pupil responses when a light is directed toward the eye
- Hyperopia, or farsightedness, which is common across many LCA subtypes
The degree of vision loss varies from child to child. Some children retain limited light perception or partial functional vision. Others have no measurable vision from birth. The specific gene mutation involved plays a major role in determining how much vision a child may have and how the condition may change over time.
Diagnosing LCA
Diagnosis typically begins when a parent or pediatrician notices that an infant is not responding visually. A full diagnosis requires a combination of clinical examination, specialized testing, and genetic analysis, each contributing important and distinct information.
A retina specialist will conduct a comprehensive examination of the eyes, including a detailed evaluation of the retina. In infancy, the retina may appear relatively normal or show only mild changes. As the child grows, more visible retinal abnormalities may develop. The examination also assesses pupil responses, eye alignment, and other physical signs that guide further testing.
Electroretinography (ERG) is one of the most important tests for diagnosing LCA. This test measures the electrical responses of the photoreceptor cells in the retina when exposed to flashes of light. In children with LCA, the ERG shows severely reduced or absent responses. Combined with early-onset vision loss, this finding strongly supports a diagnosis of LCA and helps distinguish it from other causes of poor vision in young children.
Genetic testing is essential for confirming the diagnosis and identifying the specific gene mutation involved. A blood sample or cheek swab provides the DNA needed for analysis. Knowing the exact gene variant is critical for several reasons: it helps predict how the condition may progress, it determines whether a child may be eligible for an approved treatment or an active clinical trial, and it provides information that is relevant to other family members who may carry the same variant.
A genetic counselor can help families understand their test results, the implications for siblings and future pregnancies, and how to connect with appropriate medical and community support services.
Treatment Options for LCA
Treatment for LCA depends entirely on the specific gene mutation involved. An FDA-approved gene therapy currently exists for one subtype, while research into additional subtypes is advancing steadily. For most children with LCA, supportive care and low vision services remain the primary approach.
Luxturna (voretigene neparvovec) was the first gene therapy approved by the FDA for an inherited disease. It is approved for patients who carry mutations in both copies of the RPE65 gene, a subtype that accounts for approximately 8% of LCA cases. Luxturna works by delivering a working copy of the RPE65 gene directly into retinal cells using a modified virus as a carrier. A retina specialist administers the therapy through a subretinal injection, a precisely placed injection beneath the retina.
For Luxturna to be effective, patients must have enough viable retinal cells remaining at the time of treatment. This is one of the key reasons why early diagnosis and prompt referral to a specialist experienced in inherited retinal diseases are so important. The therapy does not restore vision to normal levels, but clinical results have shown meaningful improvements in the ability to function in low-light conditions. Long-term outcomes continue to be studied, and some research has indicated that benefits may decrease over time in certain patients, highlighting the ongoing need for specialist follow-up and research into more durable treatment approaches.
For patients with CEP290 mutations, which account for approximately 15% of LCA cases, researchers have explored a different approach using CRISPR-based gene editing. CRISPR is a technology that allows scientists to make precise changes to DNA inside living cells. Early clinical research in this area has shown that a meaningful portion of participants experienced measurable improvement in vision. These treatments remain experimental and are not yet approved by the FDA for routine clinical use.
Researchers at the National Eye Institute have also investigated gene therapy approaches targeting mutations in the NPHP5 gene, which affects the ciliary structure in retinal cells. An oral medication designed to provide the retina with a usable form of vitamin A has been studied in early trials for certain LCA subtypes as well. These directions are promising but remain investigational. Families interested in clinical trial options should speak with a retina specialist who can evaluate whether a child's genetic profile and retinal health may qualify them for a current study.
For the majority of children with LCA who do not carry an RPE65 mutation, supportive care forms the foundation of management. These services focus on making the most of any residual vision and supporting independence in daily life.
- Increasing room lighting and adjusting screen brightness to enhance any available functional vision
- Working with a low vision specialist who can recommend magnification tools, adaptive devices, and screen reading software
- Orientation and mobility training to support safe and confident navigation of the environment
- Physical therapy, occupational therapy, and speech therapy to address developmental delays that can arise when a child has severely limited vision from birth
Early intervention is particularly valuable. Starting these services as soon as possible gives children the strongest foundation for learning, independence, and overall well-being.
Living With Leber Congenital Amaurosis
LCA is a lifelong condition that involves ongoing coordination among medical, developmental, and educational professionals. With the right support in place, children and adults with LCA can lead full and meaningful lives.
Early intervention programs are among the most important resources available to families. Orientation and mobility specialists teach children how to navigate both familiar and unfamiliar spaces safely. Occupational therapists address fine motor skills and activities of daily living. Schools can provide accommodations such as large-print materials, screen readers, Braille instruction, and individualized education plans tailored to the child's specific needs.
Parents and caregivers are often the most effective advocates for their child within educational and community settings. Connecting with knowledgeable professionals early and asking questions about every available service makes a real difference in outcomes.
A diagnosis of LCA can be overwhelming. Feelings of grief, fear, and uncertainty about the future are a natural response. Many families find comfort and practical guidance by connecting with others who are living with similar experiences. Organizations such as the Foundation Fighting Blindness and the National Organization for Rare Disorders offer support networks, community events, and up-to-date information about research developments.
Genetic counseling is also a valuable ongoing resource. As children grow and family circumstances change, a genetic counselor can help revisit inheritance questions, assess risks for future pregnancies, and connect families with appropriate specialists and services.
Inherited retinal disease research is one of the most rapidly advancing areas in all of eye care. New gene therapy approaches, gene editing strategies, and other experimental treatments are at various stages of development and testing. Families benefit from maintaining a long-term relationship with a retina specialist experienced in inherited retinal diseases, who can alert them to new clinical trial opportunities matched to their child's specific genetic diagnosis.
Clinical trial registries, including ClinicalTrials.gov, allow families to search for active studies using the specific gene name associated with their child's LCA subtype. Staying connected to specialized care keeps treatment options open as the science continues to evolve.
What to Expect Over Time
Understanding the typical course of LCA helps families plan ahead and make informed decisions. The outlook varies depending on the gene involved, but ongoing specialist care plays an important role for every subtype.
LCA is a lifelong condition, and most children experience severe vision loss from birth or very early in life. In some subtypes, vision remains relatively stable at a low level over many years. In others, there may be a gradual further decline as photoreceptors continue to deteriorate. The rate and extent of progression depend heavily on which gene is affected and the nature of the specific mutation involved.
Regular follow-up with a retina specialist is important even when no disease-modifying treatment is currently available. Monitoring allows for early detection of any changes, timely adjustment of supportive services, and awareness of emerging treatment options as they become available.
For patients who receive Luxturna, improvements in light sensitivity and the ability to function in low-light conditions may begin within days to weeks following the procedure. Clinical results have shown meaningful gains in navigating environments with reduced lighting. However, the therapy does not restore vision to normal levels, and patients typically continue to benefit from low vision support and adaptive tools after treatment.
Long-term outcomes are still being actively studied. Some research has indicated that the benefits of Luxturna may diminish over time in certain patients, which underscores the importance of continued specialist follow-up and ongoing investigation into more durable treatment strategies.
When to See a Retina Specialist
Early evaluation by a specialist with experience in inherited retinal diseases can significantly shape the options and support available to a child with LCA. Certain situations call for prompt referral and should not be delayed.
Any infant who shows reduced visual responsiveness, nystagmus, persistent eye rubbing, or sluggish pupil responses should be referred to a retina specialist as soon as possible. These signs in early infancy should not be attributed to normal development without a proper evaluation. An early diagnosis enables access to genetic testing, eligibility assessment for available treatments or clinical trials, and timely enrollment in developmental support services that benefit the child's long-term growth.
Because LCA is rare and genetically complex, families benefit from working with a retina specialist experienced in inherited retinal diseases and familiar with the current landscape of gene therapy and active research. These specialists coordinate genetic testing, monitor retinal health over time, and provide guidance as new options emerge.
For children identified as having RPE65 mutations, timely referral to a center equipped to administer Luxturna is especially important. Gene therapy achieves its best results when viable retinal cells are still present in sufficient numbers. The sooner an eligible child is evaluated, the better the potential for a meaningful outcome.
Frequently Asked Questions
Here are answers to questions we commonly hear from families navigating an LCA diagnosis.
LCA is not included in standard newborn screening programs. However, if both parents are confirmed carriers of a specific LCA gene variant, prenatal genetic testing during pregnancy may be an option. Preimplantation genetic testing during in vitro fertilization (IVF) can also be used to screen embryos before implantation is attempted. These are deeply personal decisions that require thoughtful guidance from a genetic counselor and a reproductive medicine specialist who can explain the full range of options and their implications.
Not yet. The only FDA-approved gene therapy for LCA is Luxturna, which applies exclusively to patients with mutations in both copies of the RPE65 gene, representing approximately 8% of cases. Research is actively underway for other subtypes, including CRISPR-based editing for CEP290 mutations and gene therapy approaches targeting NPHP5-related LCA, but none of these are currently approved for routine clinical use. A retina specialist can review your child's genetic results and advise on any trials that may be relevant to their specific subtype.
The answer depends significantly on the gene involved and the nature of the specific mutation. Some children retain limited light perception or partial functional vision throughout life, while others have very little measurable vision from birth. A retina specialist who has reviewed your child's genetic test results is best positioned to provide a realistic and individualized picture of what to expect. In all cases, supportive strategies and adaptive tools can substantially improve independence and quality of life regardless of the level of remaining vision.
Both are inherited retinal dystrophies that affect photoreceptor cells, and they share several genetic causes. The key distinction is timing and severity at onset. LCA produces profound vision loss from birth or very early infancy. Retinitis pigmentosa (RP) typically begins with night blindness during adolescence or early adulthood and progresses more gradually over many years. The severity of a specific mutation in a shared gene can determine whether it causes the early-onset pattern seen in LCA or the later-onset pattern of RP. Genetic testing is the most reliable way to clarify the diagnosis and guide appropriate care.
Your child's retina specialist is the best starting point, as these physicians actively track the clinical trial landscape in inherited retinal disease. They can assess whether your child's genetic profile and current retinal status make them a potential candidate for an ongoing study. You can also search ClinicalTrials.gov directly using your child's specific gene name. Patient organizations such as the Foundation Fighting Blindness maintain updated databases of trials for inherited retinal diseases and can help connect families with research opportunities and peer support networks.
In the majority of cases, LCA affects vision only. However, a small number of subtypes, particularly those involving certain ciliary genes, may be associated with conditions that affect other organ systems such as the kidneys. These are referred to as syndromic forms of LCA. Genetic testing results help determine whether any broader medical evaluation is warranted. Your retina specialist will discuss this possibility based on the specific gene identified in your child's testing, and can coordinate care with other specialists when appropriate.
Expert Inherited Retina Care in Connecticut
At New England Retina Associates, our fellowship-trained vitreoretinal surgeons bring specialized expertise to the evaluation and management of inherited retinal conditions, including LCA, and are proud to serve families across Connecticut. We understand how much is at stake when a family receives this diagnosis, and we are committed to providing thorough evaluation, honest guidance on available and emerging treatments, and compassionate long-term care. If your child has been referred for evaluation of LCA or another inherited retinal condition, we welcome you to our practice and are here to support your family at every step.
30 Years of Care & Commitment
